C6 Peptide Test: A Key to Diagnosis of Early Lyme disease?Ritu Ramdeo Vyas*, Seon Song and Deborah S Asnis
Department of Internal Medicine, Flushing Hospital Medical Center, Flushing, NY, USA
- *Corresponding Author:
- Ritu Ramdeo Vyas, MBBS
Flushing Hospital Medical Center
Flushing, New York United States
E-mail: [email protected]
Received Date: May 27, 2014; Accepted Date: June 28, 2014; Published Date: July 07, 2014
Citation: Vyas RR (2013) C6 Peptide Test: A Key to Diagnosis of Early Lyme disease?. Clin Microbial 3:158. doi: 10.4172/2327-5073.1000158
Copyright: © 2014 Vyas RR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Lyme disease is a multisystem disease caused by infection with Borrelia. Cardiac involvement occurs during the disseminated phase of the disease, usually within weeks to a few months after the onset of infection. The most common clinical feature of Lyme carditis is atrioventricular (AV) conduction block, however, it can also cause cardiomyopathy and myopericarditis. With widespread travel, we need tests that have high sensitivity, irrespective of the borrelial species and the area where it was acquired. We believe that C6 peptide test will help us diagnose imported Lyme disease earlier in the course than the current CDC recommended two-tiered approach which might result in delayed or missed diagnosis.